This is supported by a more recent study, in which it was reported that multiple variables, such as molecular markers (e.g., KRAS mutations), tumor location with the other clinical-pathological variables, and microsatellite status, could be used in combination to determine the prognosis and act as predictive factors in stage I-III CRC [55]. The gene discussed is KRAS; the disease is neoplasm.